Donald Trump’s actions pressuring the NHS to increase spending on medications could lead to job losses and extended wait times for patients, according to health authorities.
The NHS Confederation and NHS Providers, representing various healthcare organizations, issued a joint statement highlighting the financial challenges caused by the need to cover redundancies, potential strikes, and higher medication costs which were not accounted for in this year’s budget. The Labour Party’s NHS recovery efforts are at risk as negotiations for a US trade deal could force the NHS to pay significantly more for drugs.
A proposed agreement to raise drug “value for money” thresholds by 25% is expected to create a significant deficit in the NHS budget, resulting in delays for patients seeking treatment.
US President Donald Trump had threatened substantial tariffs on drug imports from UK companies if the NHS did not agree to higher prices. This threat prompted pharmaceutical companies to reduce investments in the UK due to the low drug prices negotiated by the NHS.
NHS Providers’ CEO, Daniel Elkeles, emphasized the difficult decision faced by the NHS of either balancing the books or cutting waiting lists, potentially leading to deficits that could impact services. Matthew Taylor, CEO of the NHS Confederation, warned that unexpected costs like redundancy payments and increased drug prices could jeopardize progress on waiting time targets and broader NHS reforms.
NHS leaders estimate that a potential deal with the US could cost the NHS around £1.5 billion this year, adding to existing financial commitments such as £1 billion for staff redundancies resulting from the merger of NHS England back into the Department of Health and Social Care.
The financial strain could force NHS trusts to limit certain services, potentially impacting patient care and leading to longer waiting times. The looming funding shortfall may result in trusts scaling back on non-essential procedures and services to manage the budget constraints.
Chancellor Rachel Reeves is set to present the UK’s autumn budget on November 26, with ongoing discussions between Health Secretary Wes Streeting and the Treasury.
A spokesperson for the Department for Health and Social Care highlighted the government’s substantial investment in the NHS but stressed the need for accompanying reforms to drive progress and efficiency within the health service.
Recent data shows a 5.8% increase in activity by NHS acute hospital trusts in England between 2024 and 2025, with a 3% rise in costs leading to a 2.7% growth in overall productivity. However, progress in tackling the backlog of patients awaiting routine treatments has stalled, indicating ongoing challenges for the NHS.
NHS leaders continue to express their commitment to delivering high levels of activity and productivity improvements but stress the necessity of upfront funding support from the government to address financial pressures and safeguard patient services. The current financial circumstances require an honest discussion about the achievable goals for the NHS in the upcoming year and aligning priorities with the government’s long-term healthcare plan.
